You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 29, 2025

Claims for Patent: 10,544,232

✉ Email this page to a colleague

Summary for Patent: 10,544,232

Title:	Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
Abstract:	The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to patients with heterozygous familial hypercholesterolemia a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with heterozygous familial hypercholesterolemia who are not adequately controlled by maximum tolerated dose statin therapy with or without other lipid lowering therapy.
Inventor(s):	Marie Baccara-Dinet, Corinne HANOTIN, Laurence Bessac, Umesh CHAUDHARI, Robert C. PORDY, William J. Sasiela, Daniel A. Schwemmer Gipe
Assignee:	Sanofi Biotechnology SAS , Regeneron Pharmaceuticals Inc
Application Number:	US14/801,384

Details for Patent 10,544,232

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	PRALUENT	alirocumab	Injection	125559	July 24, 2015	⤷ Get Started Free	2035-07-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,544,232

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
South Africa	201700195	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2016011256	⤷ Get Started Free
United States of America	2025059300	⤷ Get Started Free
United States of America	2022315669	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.